|
1.
|
Masseria C: Colorectal cancer in Italy: a
review of current national and regional practice on screening and
treatment. Eur J Health Econ. 10(Suppl 1): S41–S49. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Muzny DM, et al: Comprehensive molecular
characterization of human colon and rectal cancer. Nature.
487:330–337. 2012. View Article : Google Scholar
|
|
3.
|
Demant P: Cancer susceptibility in the
mouse: genetics, biology and implications for human cancer. Nat Rev
Genet. 4:721–734. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Sjoblom T, Jones S, Wood LD, et al: The
consensus coding sequences of human breast and colorectal cancers.
Science. 314:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Bass AJ, Lawrence MS, Brace LE, et al:
Genomic sequencing of colorectal adenocarcinomas identifies a
recurrent VTI1A-TCF7L2 fusion. Nat Genet. 43:964–968. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Persico MG, Liguori GL, Parisi S, D’Andrea
D, Salomon DS and Minchiotti G: Cripto in tumors and embryo
development. Biochim Biophys Acta. 1552:87–93. 2001.PubMed/NCBI
|
|
7.
|
Minchiotti G, Parisi S, Liguori GL,
D’Andrea D and Persico MG: Role of the EGF-CFC gene cripto in cell
differentiation and embryo development. Gene. 287:33–37. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
de Castro NP, Rangel MC, Nagaoka T,
Salomon DS and Bianco C: Cripto-1: an embryonic gene that promotes
tumorigenesis. Future Oncol. 6:1127–1142. 2010.
|
|
9.
|
Gray PC and Vale W: Cripto/GRP78
modulation of the TGF-β pathway in development and oncogenesis.
FEBS Lett. 586:1836–1845. 2012.PubMed/NCBI
|
|
10.
|
Colas JF and Schoenwolf GC: Subtractive
hybridization identifies chick-cripto, a novel EGF-CFC ortholog
expressed during gastrulation, neurulation and early cardiogenesis.
Gene. 255:205–217. 2000. View Article : Google Scholar
|
|
11.
|
Salomon DS, Bianco C, Ebert AD, et al: The
EGF-CFC family: novel epidermal growth factor-related proteins in
development and cancer. Endocr Relat Cancer. 7:199–226. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Shen MM and Schier AF: The EGF-CFC gene
family in vertebrate development. Trends Genet. 16:303–309. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Ding J, Yang L, Yan YT, Chen A, Desai N,
Wynshaw-Boris A and Shen MM: Cripto is required for correct
orientation of the anterior-posterior axis in the mouse embryo.
Nature. 395:702–707. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Liguori GL, Echevarria D, Improta R, et
al: Anterior neural plate regionalization in cripto null mutant
mouse embryos in the absence of node and primitive streak. Dev
Biol. 264:537–549. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Minchiotti G, Parisi S, Liguori G, et al:
Membrane-anchorage of Cripto protein by
glycosylphosphatidylinositol and its distribution during early
mouse development. Mech Dev. 90:133–142. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Chu J, Ding J, Jeays-Ward K, Price SM,
Placzek M and Shen MM: Non-cell-autonomous role for Cripto in axial
midline formation during vertebrate embryogenesis. Development.
132:5539–5551. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Bianco C, Rangel MC, Castro NP, et al:
Role of Cripto-1 in stem cell maintenance and malignant
progression. Am J Pathol. 177:532–540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Massague J, Blain SW and Lo RS: TGF beta
signaling in growth control, cancer, and heritable disorders. Cell.
103:295–309. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Adkins HB, Bianco C, Schiffer SG, et al:
Antibody blockade of the Cripto CFC domain suppresses tumor cell
growth in vivo. J Clin Invest. 112:575–587. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Gray PC, Shani G, Aung K, Kelber J and
Vale W: Cripto binds transforming growth factor beta (TGF-beta) and
inhibits TGF-beta signaling. Mol Cell Biol. 26:9268–9278. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Nagaoka T, Karasawa H, Turbyville T, et
al: Cripto-1 enhances the canonical Wnt/beta-catenin signaling
pathway by binding to LRP5 and LRP6 co-receptors. Cell Signal.
25:178–189. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Shani G, Fischer WH, Justice NJ, Kelber
JA, Vale W and Gray PC: GRP78 and Cripto form a complex at the cell
surface and collaborate to inhibit transforming growth factor beta
signaling and enhance cell growth. Mol Cell Biol. 28:666–677. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kelber JA, Panopoulos AD, Shani G, et al:
Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic
Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene.
28:2324–2336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Ciardiello F, Kim N, Saeki T, et al:
Differential expression of epidermal growth factor-related proteins
in human colorectal tumors. Proc Natl Acad Sci USA. 88:7792–7796.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Saeki T, Stromberg K, Qi CF, et al:
Differential immunohistochemical detection of amphiregulin and
cripto in human normal colon and colorectal tumors. Cancer Res.
52:3467–3473. 1992.
|
|
26.
|
Ciardiello F, Tortora G, Bianco C, et al:
Inhibition of CRIPTO expression and tumorigenicity in human colon
cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene.
9:291–298. 1994.PubMed/NCBI
|
|
27.
|
De Luca A, Casamassimi A, Selvam MP, et
al: EGF-related peptides are involved in the proliferation and
survival of MDA-MB-468 human breast carcinoma cells. Int J Cancer.
80:589–594. 1999.PubMed/NCBI
|
|
28.
|
Normanno N, De Luca A, Bianco C, et al:
Cripto-1 over-expression leads to enhanced invasiveness and
resistance to anoikis in human MCF-7 breast cancer cells. J Cell
Physiol. 198:31–39. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Wu Z, Li G, Wu L, Weng D, Li X and Yao K:
Cripto-1 over-expression is involved in the tumorigenesis of
nasopharyngeal carcinoma. BMC Cancer. 9:3152009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Bianco C, Strizzi L, Mancino M, et al:
Identification of cripto-1 as a novel serologic marker for breast
and colon cancer. Clin Cancer Res. 12:5158–5164. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Bianco C, Strizzi L, Normanno N, Khan N
and Salomon DS: Cripto-1: an oncofetal gene with many faces. Curr
Top Dev Biol. 67:85–133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Strizzi L, Bianco C, Normanno N, et al:
Epithelial mesenchymal transition is a characteristic of
hyperplasias and tumors in mammary gland from MMTV-Cripto-1
transgenic mice. J Cell Physiol. 201:266–276. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Strizzi L, Bianco C, Hirota M, et al:
Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic
mice. J Pathol. 211:36–44. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Sun Y, Strizzi L, Raafat A, et al:
Overexpression of human Cripto-1 in transgenic mice delays mammary
gland development and differentiation and induces mammary
tumorigenesis. Am J Pathol. 167:585–597. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Wechselberger C, Strizzi L, Kenney N, et
al: Human Cripto-1 overexpression in the mouse mammary gland
results in the development of hyperplasia and adenocarcinoma.
Oncogene. 24:4094–4105. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Xu C, Liguori G, Persico MG and Adamson
ED: Abrogation of the Cripto gene in mouse leads to failure of
postgastrulation morphogenesis and lack of differentiation of
cardiomyocytes. Development. 126:483–494. 1999.PubMed/NCBI
|
|
37.
|
Bissahoyo A, Pearsall RS, Hanlon K, et al:
Azoxymethane is a genetic background-dependent colorectal tumor
initiator and promoter in mice: effects of dose, route, and diet.
Toxicol Sci. 88:340–345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Guda K, Giardina C, Nambiar P, Cui H and
Rosenberg DW: Aberrant transforming growth factor-beta signaling in
azoxymethane-induced mouse colon tumors. Mol Carcinog. 31:204–213.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Nambiar PR, Girnun G, Lillo NA, Guda K,
Whiteley HE and Rosenberg DW: Preliminary analysis of azoxymethane
induced colon tumors in inbred mice commonly used as transgenic/
knockout progenitors. Int J Oncol. 22:145–150. 2003.PubMed/NCBI
|
|
40.
|
Liguori GL, Borges AC, D’Andrea D, et al:
Cripto-independent Nodal signaling promotes positioning of the A-P
axis in the early mouse embryo. Dev Biol. 315:280–289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Liguori GL, Echevarria D, Bonilla S, et
al: Characterization of the functional properties of the
neuroectoderm in mouse Cripto(−/−) embryos showing severe
gastrulation defects. Int J Dev Biol. 53:549–557. 2009.PubMed/NCBI
|
|
42.
|
Amundson SA, Myers TG and Fornace AJ Jr:
Roles for p53 in growth arrest and apoptosis: putting on the brakes
after genotoxic stress. Oncogene. 17:3287–3299. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Aizu W, Guda K, Nambiar P, et al: p53 and
its co-activator p300 are inversely regulated in the mouse colon in
response to carcinogen. Toxicol Lett. 144:213–224. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Saad RS, Kordunsky L, Liu YL, Denning KL,
Kandil HA and Silverman JF: Lymphatic microvessel density as
prognostic marker in colorectal cancer. Mod Pathol. 19:1317–1323.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Rangel MC, Karasawa H, Castro NP, Nagaoka
T, Salomon DS and Bianco C: Role of Cripto-1 during
epithelial-to-mesenchymal transition in development and cancer. Am
J Pathol. 180:2188–2200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Takahashi M, Fukuda K, Sugimura T and
Wakabayashi K: Beta-catenin is frequently mutated and demonstrates
altered cellular location in azoxymethane-induced rat colon tumors.
Cancer Res. 58:42–46. 1998.PubMed/NCBI
|
|
47.
|
Lee AS: GRP78 induction in cancer:
therapeutic and prognostic implications. Cancer Res. 67:3496–3499.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Huang S, Chen Y, Podsypanina K and Li Y:
Comparison of expression profiles of metastatic versus primary
mammary tumors in MMTV-Wnt-1 and MMTV-Neu transgenic mice.
Neoplasia. 10:118–124. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Saccone S, Rapisarda A, Motta S, Dono R,
Persico GM and Della Valle G: Regional localization of the human
EGF-like growth factor CRIPTO gene (TDGF-1) to chromosome 3p21. Hum
Genet. 95:229–230. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Lerman MI and Minna JD: The 630-kb lung
cancer homozygous deletion region on human chromosome 3p21.3:
identification and evaluation of the resident candidate tumor
suppressor genes. The International Lung Cancer Chromosome 3p21.3
Tumor Suppressor Gene Consortium. Cancer Res. 60:6116–6133.
2000.
|
|
51.
|
Maitra A, Wistuba II, Washington C, et al:
High-resolution chromosome 3p allelotyping of breast carcinomas and
precursor lesions demonstrates frequent loss of heterozygosity and
a discontinuous pattern of allele loss. Am J Pathol. 159:119–130.
2001. View Article : Google Scholar
|
|
52.
|
Cheng Y, Poulos NE, Lung ML, et al:
Functional evidence for a nasopharyngeal carcinoma tumor suppressor
gene that maps at chromosome 3p21.3. Proc Natl Acad Sci USA.
95:3042–3047. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Alimov A, Kost-Alimova M, Liu J, et al:
Combined LOH/CGH analysis proves the existence of interstitial 3p
deletions in renal cell carcinoma. Oncogene. 19:1392–1399. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Pardali K and Moustakas A: Actions of
TGF-beta as tumor suppressor and pro-metastatic factor in human
cancer. Biochim Biophys Acta. 1775:21–62. 2007.PubMed/NCBI
|
|
55.
|
Dong D, Ni M, Li J, et al: Critical role
of the stress chaperone GRP78/BiP in tumor proliferation, survival,
and tumor angio-genesis in transgene-induced mammary tumor
development. Cancer Res. 68:498–505. 2008. View Article : Google Scholar : PubMed/NCBI
|
